INNOVENT BIO (01801): Seven innovative products, including Xin'ermei and Xinmeiyue, successfully included in the 2026 edition of the National Reimbursement Drug List
Innovent Biologics (01801) announced that seven innovative products from Innovent Biologics have been successfully included in the new edition of the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026).
INNOVENT BIO (01801) announced that seven innovative products from INNOVENT BIO have been successfully included in the new edition of the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026).
Products newly included in the National Reimbursement Drug List for the first time include Xin'ermei (mazdutide injection, a GCG/GLP-1 dual receptor agonist), Xinmeiyue (picankibart injection, an IL-23p19 inhibitor), Dabo Xin (ipilimumab N01 injection, a CTLA-4 inhibitor), and Weifutai (quizartinib hydrochloride tablets, a type II FLT3 inhibitor); products with newly added indications included in the catalogue include Dabo Shu (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jiepali (pirtobrutinib tablets, a non-covalent BTK inhibitor); Xinbile (tafolecimab injection, a fully human PCSK9 monoclonal antibody) was successfully renewed. The new edition of the National Reimbursement Drug List will be officially implemented starting January 1, 2027.
The successful inclusion of the company's seven innovative drugs in the National Reimbursement Drug List this time covers disease areas with relatively heavy social burden, including oncology (colorectal cancer, renal cancer, hematologic malignancies), cardiovascular and metabolic diseases, and autoimmune diseases. The inclusion of the relevant products in medical insurance will further enhance the accessibility and affordability of medications for patients, allowing more LBX Pharmacy Chain Joint Stock to benefit. To date, INNOVENT BIO's lineup of innovative drugs covered by medical insurance has expanded to 17, cumulatively benefiting more than 20 million patients, continuously strengthening patient medication security with innovative achievements. Adhering to its corporate mission of "developing high-quality biologics that LBX Pharmacy Chain Joint Stock can afford," INNOVENT BIO has always placed patient needs at its core, actively responding to the call of the "Healthy China 2030" strategy, and using practical actions to help build the national health security system and promote continuous improvement in health equity. The company will actively cooperate with the implementation of medical insurance policies in various pooling regions, so that high-quality innovative drugs can benefit thousands of households faster and more widely.
Related Articles

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer
BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer






